NCT05529654CompletedNot Applicable
IMpella-Protected cArdiaC Surgery Trial (IMPACT)
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Abiomed Inc.
- Enrollment
- 100
- Locations
- 40
- Primary Endpoint
- Composite of All-Cause Mortality
Study Overview
Brief Summary
The purpose of this Trial is to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients, with the overall aim to evaluate if using Impella 5.5 with SmartAssist (Impella 5.5) peri-operatively improves early hemodynamics, end-organ function and clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.
Detailed Description
This is a prospective single-armed Trial to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients. A concurrent Registry will also be performed to collect information on patients meeting Exclusion Criteria and those not approached for enrollment. The overall aim is to evaluate if using Impella 5.5 peri-operatively improves early hemodynamics, end-organ function and subsequent clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Hemodynamically stable patients undergoing one of the following cardiac surgery procedures on CPB including aortic cross-clamping and cardioplegic arrest:
- •Isolated CABG
- •Isolated mitral valve repair or mitral valve replacement (MVR)
- •Isolated biological aortic valve replacement (AVR)
- •At least two of the following: CABG, MVR, AVR, or tricuspid valve repair or replacement (TVR)
- •Additional concomitant procedures permitted:
- •Atrial septal defect (ASD) or patent foramen ovale (PFO) repair or closure
- •Atrial fibrillation ablation procedures
- •Left atrial ablation (all forms including complete left/right side Cox Maze)
- •Coronary endarterectomy
- •LVEF within 30 days before surgery of either:
- •≤25% measured by echocardiogram or cardiac MRI, OR
- •LVEF ≤35%, measured as above, for patients with significant mitral regurgitation (MR 3+ or 4+) and planned corrective mitral valve surgery (including MV replacement or repair)
- •Any subject with EF <20% must have viability assessment performed to assess CABG candidacy (MRI preferred)
- •Age 18 years or older
- •Subject (or subject's LAR, if allowed by IRB) has signed Informed Consent Form
Exclusion Criteria
- •Salvage operation (cardiac arrest within 24 hours prior to index surgery)
- •Unresponsive state within 24 hours of the time of surgery
- •Any inotrope within 72 hours of surgery
- •Any MCS device (such as IABP, ECMO, Impella®, CentriMag™ or TandemHeart®) in place at time of informed consent and less than 24 hours prior to index study procedure
- •RV dysfunction requiring mechanical or inotropic support pre-operatively and/or likely to be needed post-operatively
- •Index procedures requiring total circulatory arrest (TCA), such as aortic arch replacement, planned durable LVAD, durable RVAD, planned right-sided temporary mechanical support of any kind, total artificial heart (TAH), cardiac transplantation, pericardiectomy, pulmonary thromboendarterectomy and septal myectomy
- •Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade or other conditions in which cardiac output is dependent on venous return
- •Ventricular septal defect (VSD)
- •Stroke within 30 days of the index cardiac surgical procedure
- •Prior mantle field chest irradiation
- •Prior solid organ or hematologic transplantation (heart, kidney, liver, lung, pancreas, bone marrow) or durable LVAD
- •History of chronic dialysis
- •Pre-existing liver dysfunction defined as: Child-Pugh Class B or C
- •Pre-existing pulmonary disease requiring home oxygen or "severe pulmonary disease" determined by enrolling Investigator
- •Systemic active infection or evidence of systemic bacterial, fungal or viral infection within 72 hours before surgery (blood culture positive with leukocytosis)
- •Confirmed COVID-19 infection within two weeks prior to operation
- •Suspected or known pregnancy
- •Participation in the active treatment or follow-up phase of another interventional clinical trial of an investigational drug or device which has not reached its primary endpoint
- •Known contraindication to heparin; History of bleeding diathesis or known coagulopathy or will refuse blood transfusions
- •Inability to perform aortic cross-clamp, such as due to porcelain aorta
- •Any contraindication or inability to place Impella 5.5 (per the IFU), including LV thrombus and/or presence of a mechanical aortic valve
- •Any organ condition, concomitant disease (e.g., psychiatric illness, current severe alcoholism or current drug abuse, cancer, hepatic or kidney disease), with life expectancy of ≤2 years or other abnormality that itself or the treatment of which could interfere with the conduct of the trial or that, in the opinion of the investigator and/or Sponsor's medical monitor, would pose an unacceptable risk to the patient in the trial.
- •Patient has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with trial procedures
- •Patient belongs to a vulnerable population [Vulnerable patient populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention]
Arms & Interventions
Impella Arm
Experimental
Impella 5.5 with SmartAssist
Intervention: Impella 5.5 with SmartAssist (Device)
Outcomes
Primary Outcomes
Composite of All-Cause Mortality
Time Frame: 90 days
Stroke (as defined by STS)
Time Frame: 90 days
New requirement for Renal Replacement Therapy (RRT)
Time Frame: 90 days
Rate of Post-Cardiotomy Cardiac Failure
Time Frame: Hospital discharge, usually within 30 days
The rate of post-cardiotomy cardiac failure evaluated at hospital discharge.
Secondary Outcomes
- Number of attempts to wean from CPB(Intra-op, usually within 1 day)
- Duration of mechanical ventilation(ICU discharge, usually within 30 days)
- Duration and dosages of inotropes and vasopressors. Duration of mechanical circulatory support (Hours)(ICU Discharge, usually within 30 days)
- Acute Kidney Injury(within 7 days or at ICU Discharge (usually within 30 days))
- Vasoactive-inotropic score (VIS)(ICU Discharge, usually within 30 days)
- Cardiovascular mortality(Hospital discharge, usually within 30 days)
- Major Hemolysis(Hospital Discharge, usually within 30 days)
- Major Vascular Complications(Hospital Discharge, usually within 30 days)
- Major Bleeding(Hospital Discharge, usually within 30 days)
- Length of ICU Stay(ICU Discharge, usually within 30 days)
- Length of Hospital Stay(Hospital Discharge, usually within 30 days)
- Quality of Life (QoL) assessed by KCCQ(90 Days Post-Op)
- Physical Activity(90 Days Post-Op)
- Technical Success(Intra-op, usually within 1 day)
Investigators
Study Sites (40)
Loading locations...
Similar Trials
Completed
Phase 1
Pericardic Adipose Pedicle Transposition Over the Myocardial Infarct (adiFLAP Trial)Myocardial InfarctionNCT01473433Germans Trias i Pujol Hospital10
Terminated
Not Applicable
Safety and Effectiveness Study of Perceval S Valve for Extended CE MarkAortic Valve ReplacementNCT01368666Corcym S.r.l658
Terminated
Not Applicable
Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the ElderlyMyocardial InfarctionCoronary Artery DiseaseCongestive Heart FailureCardiomyopathyNCT02121158VA Office of Research and Development167
Recruiting
Phase 1
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 DiabetesType 1 DiabetesDiabetes Mellitus, Type 1NCT05626712Creative Medical Technology Holdings Inc18
Active, not recruiting
Not Applicable
TRILUMINATE Pivotal TrialTricuspid RegurgitationNCT03904147Abbott Medical Devices572